Literature DB >> 29024810

MAGEA6 promotes human glioma cell survival via targeting AMPKα1.

Si-Jian Pan1, Jie Ren1, Hong Jiang1, Wei Liu2, Liang-Yun Hu2, Yi-Xin Pan2, Bomin Sun2, Qing-Fang Sun3, Liu-Guan Bian4.   

Abstract

Melanoma antigen A6 (MAGEA6)/TRIM28 complex is a cancer-specific ubiquitin ligase, which degradates tumor suppressor protein AMP-activated protein kinase (AMPK). We show that MAGEA6 is uniquely expressed in human glioma tissues and cells, which is correlated with AMPKα1 downregulation. It is yet absent in normal brain tissues and human astrocytes/neuronal cells. MAGEA6 knockdown by targeted-shRNA in glioma cells restored AMPKα1 expression, causing mTORC1 in-activation and cell death/apoptosis. Reversely, AMPKα1 knockdown or mutation ameliorated glioma cell death by MAGEA6 shRNA. In vivo, Glioma xenograft tumor growth in mice was largely inhibited following expressing MAGEA6 shRNA. AMPKα1 upregulation and mTORC1 inhibition were observed in MAGEA6 shRNA-bearing xenograft tissues. Collectively, MAGEA6 promotes glioma cell survival possibly via targeting AMPKα1.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMPK; Glioma; MAGEA6; mTOR and oncotarget

Mesh:

Substances:

Year:  2017        PMID: 29024810     DOI: 10.1016/j.canlet.2017.09.051

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

Review 1.  Emerging roles of the MAGE protein family in stress response pathways.

Authors:  Rebecca R Florke Gee; Helen Chen; Anna K Lee; Christina A Daly; Benjamin A Wilander; Klementina Fon Tacer; Patrick Ryan Potts
Journal:  J Biol Chem       Date:  2020-09-13       Impact factor: 5.157

2.  Regulation of MAGE-A3/6 by the CRL4-DCAF12 ubiquitin ligase and nutrient availability.

Authors:  Ramya Ravichandran; Kiran Kodali; Junmin Peng; Patrick Ryan Potts
Journal:  EMBO Rep       Date:  2019-05-24       Impact factor: 8.807

3.  TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.

Authors:  Ka-Wing Fong; Jonathan C Zhao; Bing Song; Bin Zheng; Jindan Yu
Journal:  Nat Commun       Date:  2018-11-27       Impact factor: 14.919

4.  Lnc-THOR silencing inhibits human glioma cell survival by activating MAGEA6-AMPK signaling.

Authors:  Jun Xue; Shan Zhong; Bo-Min Sun; Qing-Fang Sun; Liang-Yun Hu; Si-Jian Pan
Journal:  Cell Death Dis       Date:  2019-11-14       Impact factor: 8.469

5.  MicroRNA-769-5p Promotes The Growth Of Glioma Cells By Targeting Lysine Methyltransferase 2A.

Authors:  Mingze Chang; Peng Yan; Bei Zhang; Gejuan Zhang; Juanhong Wang; Hanming Ge; Nannan Han; Chengxue Du; Wenzhen Shi; Ye Tian
Journal:  Onco Targets Ther       Date:  2019-11-05       Impact factor: 4.345

6.  MAGEA6 positively regulates MSMO1 and promotes the migration and invasion of oesophageal cancer cells.

Authors:  Manyu Liu; Jintao Li; Yangjunqi Wang; Maliha Ghaffar; Yishu Yang; Minglian Wang; Changshuo Li
Journal:  Exp Ther Med       Date:  2022-01-07       Impact factor: 2.447

7.  A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma.

Authors:  Guoqing Ouyang; Bin Yi; Guangdong Pan; Xiang Chen
Journal:  Cancer Cell Int       Date:  2020-06-03       Impact factor: 5.722

8.  Long non-coding RNA LBX2-AS1 enhances glioma proliferation through downregulating microRNA-491-5p.

Authors:  Qunbang Chen; Jian Gao; Yingjia Zhao; Ruizhe Hou
Journal:  Cancer Cell Int       Date:  2020-08-26       Impact factor: 5.722

9.  Exopolysaccharides isolated from Rhizopus nigricans induced colon cancer cell apoptosis in vitro and in vivo via activating the AMPK pathway.

Authors:  Yan Lu; Xiujuan Zhang; Jiayue Wang; Kaoshan Chen
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

10.  The therapeutic value of XL388 in human glioma cells.

Authors:  Shan Zhong; Jun Xue; Jiao-Jiao Cao; Bomin Sun; Qing-Fang Sun; Liu-Guan Bian; Liang-Yun Hu; Si-Jian Pan
Journal:  Aging (Albany NY)       Date:  2020-11-06       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.